Cara Therapeutics (CARA): 3Q Looks Fine But 2017 Catalysts Are Key - HC Wainwright
Tweet Send to a Friend
H.C. Wainwright analyst, Corey Davis, reiterated his Buy rating on shares of Cara Therapeutics (NASDAQ: CARA) noting 3 key potential ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE